Cancer risk in patients with psoriasis: should we be paying more attention?

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392.
   PubMed Web of Science ®Google Scholar
• Loft ND, Egeberg A, Rasmussen MK, et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a danish nationwide study. Acta Derm Venereol. 2019;99(13):1224–1230.
   PubMed Web of Science ®Google Scholar
• Hesselvig JH, Egeberg A, Loft ND, et al. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol. 2018;98(3–4):335–339.
   PubMed Web of Science ®Google Scholar
• Miller IM, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014–1024.
   PubMed Web of Science ®Google Scholar
• Olivier C, PD R, Daihung D, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–895.
   PubMedGoogle Scholar
• Gladman D, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(suppl2):ii14–ii17.
   PubMedGoogle Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265. e19.
   PubMed Web of Science ®Google Scholar
• Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633–639.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Harskamp C, Dhillon J, et al. Psoriasis and smoking: a systematic review and meta‐analysis. Br J Dermatol. 2014;170(2):304–314.
   PubMed Web of Science ®Google Scholar
• Brenaut E, Horreau C, Pouplard C, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27:30–35.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim HJ, Han KD, et al. Cancer risk in 892 089 patients with psoriasis in Korea: A nationwide population‐based cohort study. J Dermatol. 2019;46(2):95–102. .
   PubMed Web of Science ®Google Scholar
• Shoo BA, Sagebiel RW, Kashani-Sabet M. Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol. 2010;62(5):751–756.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Thyssen JP, Gislason G, et al. Skin cancer in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016;30(8):1349–1353.
   PubMed Web of Science ®Google Scholar
• Vaengebjerg S, Skov L, Egeberg A, et al., Prevalence, incidence and risk of cancer in patients with psoriasis and psoriatic arthritis: A systematic review and meta–analysis. JAMA Dermatol. 2020:156(4):421.
   PubMed Web of Science ®Google Scholar
• Trafford AM, Parisi R, Kontopantelis E, et al., Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(12):1390–1403.
   PubMed Web of Science ®Google Scholar
• Samarasekera E, Sawyer L, Parnham J, et al. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012;345:e6712.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174.
   PubMed Web of Science ®Google Scholar
• Halprin KM, Comerford M, Taylor JR. Cancer in patients with psoriasis. J Am Acad Dermatol. 1982;7(5):633–638.
   PubMed Web of Science ®Google Scholar
• Bailin PL, Tindall JP, Roenigk HH, et al. Is methotrexate therapy for psoriasis carcinogenic?: A modified retrospective-prospective analysis. Jama. 1975;232(4):359–362.
   PubMed Web of Science ®Google Scholar
• Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137(6):778–783.
   PubMedGoogle Scholar
• Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta‐analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27:36–46.
   PubMed Web of Science ®Google Scholar
• Kamstrup M, Skov L, Zachariae C, et al. Psoriasis and risk of malignant lymphoma: a population‐based cohort study. Br J Dermatol. 2018;178(6):1435–1436.
   PubMed Web of Science ®Google Scholar
• Fuxench ZCC, Shin DB, Beatty AO, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol. 2016;152(3):282–290. .
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, editor. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. 2013. Springer. DOI:10.1007/s00281-012-0352-6.
   PubMed Web of Science ®Google Scholar
• Dmitrieva-Posocco O, Dzutsev A, Posocco DF, et al. Cell-type-specific responses to interleukin-1 control microbial invasion and tumor-elicited inflammation in colorectal cancer. Immunity. 2019;50(1):166–180. e7.
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749.
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15(2):103–113.
   PubMed Web of Science ®Google Scholar
• Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22(20):4794.
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med. 1991;325(13):928–937.
   PubMed Web of Science ®Google Scholar
• Francescone R, Hou V, Grivennikov SI, et al. colitis-associated cancer. Inflamm Bowel Dis. 2015;21(2):409–418.
   PubMed Web of Science ®Google Scholar
• Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000;60(13):3333–3337.
   PubMed Web of Science ®Google Scholar
• Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105(7):1480.
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124(5):1022–1030. e395.
   PubMed Web of Science ®Google Scholar
• Hijnen D, Knol EF, Gent YY, et al. CD8+ T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22. J Invest Dermatol. 2013;133(4):973–979.
   PubMed Web of Science ®Google Scholar
• Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342–350.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
   PubMed Web of Science ®Google Scholar
• Cannavò SP, Riso G, Casciaro M, et al. Oxidative stress involvement in psoriasis: a systematic review. Free Radic Res. 2019;53(8):829–840.
   PubMed Web of Science ®Google Scholar
• Canli Ö, Nicolas AM, Gupta J, et al. Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell. 2017;32(6):869–883. e5.
   PubMed Web of Science ®Google Scholar
• Kim S, Ryu YW, Kwon JI, et al. Differential expression of cyclin D1, Ki‑67, pRb, and p53 in psoriatic skin lesions and normal skin. Mol Med Rep. 2018;17(1):735–742.
   PubMed Web of Science ®Google Scholar
• De Cock D, Hyrich K. Malignancy and rheumatoid arthritis: epidemiology, risk factors and management. Best Practice & Research Clinical Rheumatology. 201932(6):869–886.
   Web of Science ®Google Scholar
• Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.
   PubMed Web of Science ®Google Scholar
• Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17(1):212.
   PubMed Web of Science ®Google Scholar
• Fallah M, Liu X, Ji J, et al. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. Ann Oncol. 2014;25(7):1397–1404.
   PubMed Web of Science ®Google Scholar
• Fallah M, Liu X, Ji J, et al. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol. 2014;25(10):2025–2030.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194–2201.
   PubMed Web of Science ®Google Scholar
• Ekström K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first‐degree relatives. Arthritis Rheum. 2003;48(4):963–970.
   PubMed Web of Science ®Google Scholar
• Smedby KE, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029–4038.
   PubMed Web of Science ®Google Scholar
• Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer. 2009;124(7):1497–1502.
   PubMed Web of Science ®Google Scholar
• Söderberg KC, Jonsson F, Winqvist O, et al. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer. 2006;42(17):3028–3033.
   PubMed Web of Science ®Google Scholar
• Ngalamika O, Zhang Y, Yin H, et al. Epigenetics, autoimmunity and hematologic malignancies: a comprehensive review. J Autoimmun. 2012;39(4):451–465.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833–1842.
   PubMed Web of Science ®Google Scholar
• McAllister F, Bailey JM, Alsina J, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell. 2014;25(5):621–637.
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345.
   PubMed Web of Science ®Google Scholar
• Alinejad V, Dolati S, Motallebnezhad M, et al. The role of IL17B-IL17RB signaling pathway in breast cancer. Biomed Pharmacother. 2017;88:795–803.
   PubMed Web of Science ®Google Scholar
• Wang K, Kim MK, Di Caro G, et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity. 2014;41(6):1052–1063.
   PubMed Web of Science ®Google Scholar
• Komura T, Sakai Y, Harada K, et al. Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD 4+ T cells with clinical impact. Cancer Sci. 2015;106(6):672–686.
   PubMed Web of Science ®Google Scholar
• Chiu H-Y, Hsieh C-F, Chiang Y-T, et al. The risk of chronic pancreatitis in patients with psoriasis: a population-based cohort study. PloS One. 2016;11(7):e0160041.
   PubMed Web of Science ®Google Scholar
• Kirkegård J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112(9):1366.
   PubMed Web of Science ®Google Scholar
• Stein C, Colditz G. Modifiable risk factors for cancer. Br J Cancer. 2004;90(2):299.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Rossi M, Jahanzaib Anwar M, Usman A, et al. Colorectal cancer and alcohol consumption—populations to molecules. Cancers (Basel). 2018;10(2):38.
   PubMed Web of Science ®Google Scholar
• Korc M, Jeon CY, Edderkaoui M, et al. Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2017;31(5):529–536.
   PubMed Web of Science ®Google Scholar
• Frentz G, Olsen J. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol. 1999;140(2):237–242.
   PubMed Web of Science ®Google Scholar
• Hannuksela-Svahn A, Pukkala E, Läärä E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol. 2000;114(3):587–590.
   PubMed Web of Science ®Google Scholar
• Ji J, Shu X, Sundquist K, et al. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer. 2009;100(9):1499–1502.
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta J, Dominique A, Simon T, et al. Risk of cancer in patients with psoriasis/psoriatic arthritis: a population-based study in the province of british columbia. Vol. OP0130, BMJ Publishing Group Ltd; 2018;77:115–116.
   Google Scholar
• Brauchli YB, Jick SS, Miret M, et al. Psoriasis and risk of incident cancer: an inception cohort study with a nested case–control analysis. J Invest Dermatol. 2009;129(11):2604–2612.
   PubMed Web of Science ®Google Scholar
• Li W, Han J, Cho E, et al. Personal history of psoriasis and risk of incident cancer among women: a population-based cohort study. Br J Dermatol. 2016;174(5):1108.
   PubMed Web of Science ®Google Scholar
• Prizment AE, Alonso A, Folsom AR, et al. Association between psoriasis and incident cancer: the iowa’s women’s health study. Cancer Causes Control. 2011;22(7):1003–1010.
   PubMed Web of Science ®Google Scholar
• Boffetta P, Gridley G, Lindelöf B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol. 2001;117(6):1531–1537.
   PubMed Web of Science ®Google Scholar
• Olsen JH, Møller H, Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol. 1992;27(5):716–722.
   PubMed Web of Science ®Google Scholar
• Lee J, Jung K, Kim T, et al. Risk of malignancy in patients with psoriasis: A 15‐year nationwide population‐based prospective cohort study in Korea. J Eur Acad Dermatol Venereol. 2019. DOI:10.1111/jdv.15783.
   Web of Science ®Google Scholar
• Frentz G, Olsen J, Avrach W. Malignant tumours and psoriasis: climatotherapy at the Dead Sea. Br J Dermatol. 1999;141(6):1088–1091.
   PubMed Web of Science ®Google Scholar
• BERNE B, HANNUKSELA M, POIKOLAINEN K, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol. 1999;141:497–501.
   PubMed Web of Science ®Google Scholar
• Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120(2):211–216.
   PubMed Web of Science ®Google Scholar
• Lindelöf B, Eklund G, Liden S, et al. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol. 1990;22(6):1056–1060.
   PubMed Web of Science ®Google Scholar
• Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol. 1988;91:3.
   PubMed Web of Science ®Google Scholar
• Lan -C-CE, Ko Y-C, Yu H-S, et al. Psoriatic patients with diabetes are prone to develop digestive organ cancers: a population-based study in Taiwan. J Dermatol Sci. 2012;68(2):82–88.
   PubMed Web of Science ®Google Scholar
• Chen Y-J, Wu C-Y, Chen T-J, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011;65(1):84–91.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Liu X, Ji J, et al. Autoimmune disease and subsequent digestive tract cancer by histology. Ann Oncol. 2011;23(4):927–933.
   PubMed Web of Science ®Google Scholar
• Alderson M, Clarke J. Cancer incidence in patients with psoriasis. Br J Cancer. 1983;47(6):857.
   PubMed Web of Science ®Google Scholar
• Roelofzen JH, Aben KK, Oldenhof UT, et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol. 2010;130(4):953–961.
   PubMed Web of Science ®Google Scholar
• Liu X, Ji J, Forsti A, et al. Autoimmune disease and subsequent urological cancer. J Urol. 2013;189(6):2262–2268.
   PubMed Web of Science ®Google Scholar
• Phan K, Onggo J, Charlton O, et al. Relationship between psoriasis and non‐alcoholic fatty liver disease–Updated systematic review and adjusted meta‐analysis. Australas J Dermatol. 2019. DOI:10.1111/ajd.13015.
   Web of Science ®Google Scholar
• Loft N, Skov L, Bryld L, et al. Treatment history of patients receiving biologic therapy for psoriasis–a Danish nationwide study. J Eur Acad Dermatol Venereol. 2017;31(8):e362–e363.
   PubMed Web of Science ®Google Scholar
• Han JH, Lee JH, Han KD, et al. Epidemiology and medication trends in patients with psoriasis: a nationwide population-based cohort study from Korea. Acta Derm Venereol. 2018;98(3–4):396–400.
   PubMed Web of Science ®Google Scholar
• Ostenfeld E, Erichsen R, Thorlacius‐Ussing O, et al. Use of systemic glucocorticoids and the risk of colorectal cancer. Aliment Pharmacol Ther. 2013;37(1):146–152.
   PubMed Web of Science ®Google Scholar
• Sørensen GV, Cronin-Fenton DP, Sørensen HT, et al. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res. 2012;14(1):R21.
   PubMed Web of Science ®Google Scholar
• Ratib S, Burden-Teh E, Leonardi-Bee J, et al. Long-term topical corticosteroid use and risk of skin cancer: a systematic review. JBI Database System Rev Implement Rep. 2018;16(6):1387–1397.
   PubMedGoogle Scholar
• Moustafa GA, Xanthopoulou E, Riza E, et al. Skin disease after occupational dermal exposure to coal tar: a review of the scientific literature. Int J Dermatol. 2015;54(8):868–879.
   PubMed Web of Science ®Google Scholar
• Geller S, Xu H, Lebwohl M, et al. Malignancy risk and recurrence with psoriasis and its treatments: a concise update. Am J Clin Dermatol. 2018;19(3):363–375.
   PubMed Web of Science ®Google Scholar
• Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol. 2005;44(5):355–360.
   PubMed Web of Science ®Google Scholar
• Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV‐A therapy and narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:22–31.
   PubMed Web of Science ®Google Scholar
• Hearn R, Kerr A, Rahim K, et al. Incidence of skin cancers in 3867 patients treated with narrow‐band ultraviolet B phototherapy. Br J Dermatol. 2008;159(4):931–935.
   PubMed Web of Science ®Google Scholar
• Weischer M, Blum A, Eberhard F, et al. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol. 2004;84:5.
   Web of Science ®Google Scholar
• McKenna K, Patterson C, Handley J, et al. Cutaneous neoplasia following PUVA therapy for psoriasis. Br J Dermatol. 1996;134(4):639–642.
   PubMed Web of Science ®Google Scholar
• Bruynzeel I, Bergman W, Hartevelt H, et al. “High single‐dose’European PUVA regimen also causes an excess of non‐melanoma skin cancer. Br J Dermatol. 1991;124(1):49–55.
   PubMed Web of Science ®Google Scholar
• Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med. 1997;336(15):1041–1045.
   PubMed Web of Science ®Google Scholar
• Stern RS, up Study PF. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol. 2001;44(5):755–761.
   PubMed Web of Science ®Google Scholar
• Stern RS, Study PF-U. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66(4):553–562.
   PubMed Web of Science ®Google Scholar
• Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol. 1999;141(1):108–112.
   PubMed Web of Science ®Google Scholar
• Chen K, Craig J, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol. 2005;152(3):518–523.
   PubMed Web of Science ®Google Scholar
• Boldeman C, Beitner H, Jansson B, et al. Sunbed use in relation to phenotype, erythema, sunscreen use and skin diseases. A questionnaire survey among Swedish adolescents. Br J Dermatol. 1996;135(5):712–716.
   PubMed Web of Science ®Google Scholar
• Turner R, Farr P, Walshaw D. Many patients with psoriasis use sunbeds. BMJ. 1998;317(7155):412.
   PubMedGoogle Scholar
• Egeberg A, Skov L, Gislason GH, et al. Incidence and prevalence of psoriasis in Denmark. Acta Derm Venereol. 2017;97(6–7):808–812.
   PubMed Web of Science ®Google Scholar
• Reich K, Mrowietz U, Radtke M, et al. Drug safety of systemic treatments for psoriasis: results from The German psoriasis registry PsoBest. Arch Dermatol Res. 2015;307(10):875–883.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Internal Med. 2008;168(4):378–381.
   PubMedGoogle Scholar
• Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol. 2006;142(9):1132–1135.
   PubMedGoogle Scholar
• Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. Dermatology. 1983;167(5):260–261.
   Google Scholar
• Carretero G, Ferrandiz C, Dauden E, et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol. 2015;29(1):156–163.
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol. 2017;77(5):845–854. e5.
   PubMed Web of Science ®Google Scholar
• deShazo R, Soltani-Arabshahi R, Krishnasamy S, et al. Non-melanoma skin cancer risk among patients in the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2019;18(10):1059–1060.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–762.
   PubMed Web of Science ®Google Scholar
• Polesie S, Gillstedt M, Sönnergren H, et al. Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry‐based cohort study. Br J Dermatol. 2017;176(6):1492–1499.
   PubMed Web of Science ®Google Scholar
• Polesie S, Gillstedt M, Paoli J, et al. Methotrexate exposure and risk of cutaneous malignant melanoma: no evidence of a dose-response relationship. Acta Derm Venereol. 2018;98(9–10):888–895.
   PubMed Web of Science ®Google Scholar
• Polesie S, Gillstedt M, Paoli J, et al. Methotrexate treatment in patients with a history of cutaneous melanoma and the risk of a consecutive primary melanoma: A national retrospective registry-based cohort study. J Am Acad Dermatol. 2017;77(1):161–163.
   PubMed Web of Science ®Google Scholar
• Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun. 1989;2(5):723–731.
   PubMed Web of Science ®Google Scholar
• Griffiths C, Dubertret L, Ellis C, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol. 2004;150(s67):11–23.
   PubMedGoogle Scholar
• Muellenhoff MW, Koo JY. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J Dermatological Treat. 2012;23(4):290–304.
   PubMed Web of Science ®Google Scholar
• Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358(9287):1042–1045.
   PubMed Web of Science ®Google Scholar
• Dunn LK, Gaar LR, Yentzer BA, et al. Acitretin in dermatology: a review. J Drugs Dermatol. 2011;10(7):772–782.
   PubMed Web of Science ®Google Scholar
• Stern RS, Fitzgerald E, Ellis CN, et al. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol. 1995;33(1):44–52.
   PubMed Web of Science ®Google Scholar
• Cheeley J, Sahn RE, DeLong LK, et al. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013;68(2):247–254.
   PubMed Web of Science ®Google Scholar
• Kim J, Park MK, Li W-Q, et al. Association of Vitamin A intake with cutaneous squamous cell carcinoma risk in the United States. JAMA Dermatol. 2019;155(11):1260–1268.
   PubMed Web of Science ®Google Scholar
• Alizadeh F, Bolhassani A, Khavari A, et al. Retinoids and their biological effects against cancer. Int Immunopharmacol. 2014;18(1):43–49.
   PubMed Web of Science ®Google Scholar
• Helm CW, Lorenz DJ, Meyer NJ, et al. Retinoids for preventing the progression of cervical intra‐epithelial neoplasia. Cochrane Database of Systematic Reviews. 2013:6. Art. No.: CD003296. DOI: 10.1002/14651858.CD003296.pub3.
   Web of Science ®Google Scholar
• Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249–261.
   PubMed Web of Science ®Google Scholar
• McKenna D, Murphy G. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol. 1999;140(4):656–660.
   PubMed Web of Science ®Google Scholar
• Huen AO, Kim EJ. The role of systemic retinoids in the treatment of cutaneous T-cell lymphoma. Dermatol Clin. 2015;33(4):715–729.
   PubMed Web of Science ®Google Scholar
• Balak DM. Fumaric acid esters in the management of psoriasis. Psoriasis (Auckland, NZ). 2015;5:9.
   PubMedGoogle Scholar
• Smith D. Fumaric acid esters for psoriasis: a systematic review. J Ir Coll Physicians Surg. 2017;186(1):161–177.
   Google Scholar
• Dickel H, Bruckner T, Altmeyer P. Long‐term real‐life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single‐centre, retrospective, observational study. J Eur Acad Dermatol Venereol. 2018;32(10):1710–1727.
   PubMed Web of Science ®Google Scholar
• Barth D, Simon JC, Wetzig T. Malignant melanoma during treatment with fumaric acid esters–coincidence or treatment‐related? J Dtsch Dermatol Ges. 2011;9(3):223–224.
   PubMed Web of Science ®Google Scholar
• Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310–317. e1.
   PubMed Web of Science ®Google Scholar
• Apalla Z, Psarakis E, Lallas A, et al. Psoriasis in patients with active lung cancer: is apremilast a safe option? Dermatol Pract Concept. 2019;9(4):300–301.
   PubMedGoogle Scholar
• Peitsch WK. Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab. J Dtsch Dermatol Ges. 2019;17(3):330–332.
   Web of Science ®Google Scholar
• Kahn JS, Casseres RG, Her MJ, et al. Treatment of psoriasis with biologics and apremilast in patients with a history of malignancy: a retrospective chart review. J Drugs Dermatol. 2019;18:4.
   Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64(10):1414–1420.
   PubMed Web of Science ®Google Scholar
• Bongartz T, AJ S, MJ S, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama. 2006;295(19):2275–2285.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009;68(7):1177–1183.
   PubMed Web of Science ®Google Scholar
• Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68(7):1136–1145.
   PubMed Web of Science ®Google Scholar
• Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1087–1093.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12(1):R5.
   PubMed Web of Science ®Google Scholar
• Raaschou P, Simard JF, Neovius M, et al. Does cancer that occurs during or after anti–tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site‐specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheumatism. 2011;63(7):1812–1822.
   PubMedGoogle Scholar
• Dreyer L, Mellemkjær L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides–a follow-up study from the DANBIO registry. Ann Rheum Dis. 2013;72(1):79–82.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Kremer JM, Fisher M, et al. editors. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. In: Saunders WB, editor. Seminars in arthritis and rheumatism (Vol. 43, No. 4, pp. 489-497). Elsevier; 2014.
   Google Scholar
• Lan J-L, Tseng C-H, Chen J-H, et al. Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor. Medicine (Baltimore). 2017;96(7):7.
   Web of Science ®Google Scholar
• Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–1050.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Rothman KJ, Kricorian G, et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol. 2015;72(1):115–122.
   PubMed Web of Science ®Google Scholar
• Asgari MM, Ray GT, Geier JL, et al. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017;76(4):632–638.
   PubMed Web of Science ®Google Scholar
• Magnano M, Loi C, Sechi A, et al. Risk of malignancy in psoriatic patients: our clinical experience. Dermatol Ther. 2017;30(4):e12476.
   Web of Science ®Google Scholar
• Napolitano M, Megna M, Patrì A, et al. Systemic treatment for psoriasis and malignancies: A real risk? Dermatol Ther. 2017;30(4):4.
   Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–714.
   PubMed Web of Science ®Google Scholar
• Wu J, Armstrong A, Singh R, et al. Adverse medical conditions across treatment options in patients with psoriasis: a claims-based analysis. J Drugs Dermatol. 2018;17(11):1211–1218.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Papp K, Strober B, et al. Comprehensive long‐term safety of adalimumab from 18 clinical trials in adult patients with moderate‐to‐severe plaque psoriasis. Br J Dermatol. 2019;180(1):76–85.
   PubMed Web of Science ®Google Scholar
• Pariser DM, Leonardi CL, Gordon K, et al. Integrated safety analysis: short-and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012;67(2):245–256.
   PubMed Web of Science ®Google Scholar
• Borren NZ, Ananthakrishnan A. P063 safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2019;25(Supplement_1):S30–S30.
   Google Scholar
• Beukelman T, Xie F, Chen L, et al. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis. 2018;77(7):1012–1016.
   PubMed Web of Science ®Google Scholar
• Mason KJ. 238 The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared to conventional systemic therapy: results from The British association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2018;138(5):S41.
   Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517–524.
   PubMed Web of Science ®Google Scholar
• Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76(2):386–391.
   PubMed Web of Science ®Google Scholar
• Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2016;151(1):97–109. e4.
   PubMed Web of Science ®Google Scholar
• Waljee AK, Higgins PD, Jensen CB, et al. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. The Lancet Gastroenterology & Hepatology. 2019;5(3):276–284.
   Web of Science ®Google Scholar
• Ergen EN, Yusuf N. Inhibition of interleukin‐12 and/or interleukin‐23 for the treatment of psoriasis: what is the evidence for an effect on malignancy? Exp Dermatol. 2018;27(7):737–747.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(2):304–314.
   PubMed Web of Science ®Google Scholar
• Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–534.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742–751.
   PubMed Web of Science ®Google Scholar
• Papp K, Griffiths C, Gordon K, et al. Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up. Br J Dermatol. 2013;168(4):844–854.
   PubMed Web of Science ®Google Scholar
• Loft ND, Vaengebjerg S, Halling AS, et al. Adverse events with IL‐17 and IL‐23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta‐analysis of phase III studies. J Eur Acad Dermatol Venereol. 2019. DOI:10.1111/jdv.16073.
   PubMedGoogle Scholar
• van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98. e4.
   PubMed Web of Science ®Google Scholar
• Strober B, Leonardi C, Papp KA, et al. Short-and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432–440. e17.
   PubMed Web of Science ®Google Scholar
• Reich K, Griffiths CE, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2019;46(12):1141–1152.
   Google Scholar
• Elmer K, George R. Cutaneous T-cell lymphoma presenting as benign dermatoses. Am Fam Physician. 1999;59(10):2809–2813.
   PubMed Web of Science ®Google Scholar